Join Growin Stock Community!

Novocure limitedNVCR.US Overview

US StockHealthcare
(No presentation for NVCR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NVCR AI Insights

NVCR Overall Performance

NVCR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NVCR Recent Performance

-1.98%

Novocure limited

0.05%

Avg of Sector

-0.31%

S&P500

NVCR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NVCR Key Information

NVCR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NVCR Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Price of NVCR

NVCR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NVCR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.34
PB Ratio
4.48
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.54%
Net Margin
-20.79%
Revenue Growth (YoY)
8.28%
Profit Growth (YoY)
4.37%
3-Year Revenue Growth
10.73%
3-Year Profit Growth
9.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.34
PB Ratio
4.48
Price-to-FCF
-
Gross Margin
74.54%
Net Margin
-20.79%
Revenue Growth (YoY)
8.28%
Profit Growth (YoY)
4.37%
3-Year Revenue Growth
10.73%
3-Year Profit Growth
9.92%

  • When is NVCR's latest earnings report released?

    The most recent financial report for Novocure limited (NVCR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NVCR's short-term business performance and financial health. For the latest updates on NVCR's earnings releases, visit this page regularly.

  • What is the operating profit of NVCR?

    According to the latest financial report, Novocure limited (NVCR) reported an Operating Profit of -40.39M with an Operating Margin of -23.17% this period, representing a growth of 36.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NVCR's revenue growth?

    In the latest financial report, Novocure limited (NVCR) announced revenue of 174.35M, with a Year-Over-Year growth rate of 8.11%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does NVCR have?

    At the end of the period, Novocure limited (NVCR) held Total Cash and Cash Equivalents of 103.39M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NVCR go with three margins increasing?

    In the latest report, Novocure limited (NVCR) did not achieve the “three margins increasing” benchmark, with a gross margin of 75.8%%, operating margin of -23.17%%, and net margin of -14.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NVCR's profit trajectory and future growth potential.

  • Is NVCR's EPS continuing to grow?

    According to the past four quarterly reports, Novocure limited (NVCR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NVCR?

    Novocure limited (NVCR)'s Free Cash Flow (FCF) for the period is -22.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 84.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.